Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1529-1536

  Chen, Allan Y ^a   Okunieff, Paul ^a   Pommier, Yves ^a   Mitchell, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; HOE 33342; RADIOSENSITIZING AGENT;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; CELL DENSITY; CHINESE HAMSTER; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; STEREOSPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZIMIDAZOLES; CAMPTOTHECIN; CELL CYCLE; CELLS, CULTURED; CRICETINAE; CRICETULUS; DNA; DNA TOPOISOMERASES, TYPE I; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0030907319     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. DeVita, V., Hellman, S., and Rosenberg, S. (eds). Cancer: Principles and Practice of Oncology, Ed. 4. Philadelphia: J. B. Lippincott Co., 1993.
2. Perez, C., and Brady, L. (eds.). Principles and Practice of Radiation Oncology, Ed. 2. Philadelphia: J. B. Lippincott Co., 1992.
3. John, M., Flam, M., Legha, S., and Phillips, T. (eds.) Chemoradiation: An Integrated Approach to Cancer Treatment, Ed. 1. Philadelphia, J. B. Lippincott Co., 1995.
4. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleotides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
5. Gellert, M. DNA topoisomerases. Annu. Rev. Biochem., 50: 879-910, 1981.
6. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665-697, 1985.
7. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
8. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
9. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
10. Hsiang, Y.-H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
11. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
12. Nitiss, J., and Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
13. Chen, A. Y., Yu, C., Gatto, B., and Liu, L. F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA, 90: 8131-8135, 1993.
14. Chen, A. Y., Yu, C., Bodley, A., Peng, L. F., and Liu, L. F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53: 1332-1337, 1993.
15. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drugstabilized topoisomerase I-DNA complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
16. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
17. Zhang, H., D'Arpa, P., and Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 2: 23-27, 1990.
18. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
19. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicolas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
20. Potmesil, M., Hsiang, Y.-H., Liu, L. F., Bank, B., Grossberg, H., Kirshenbaum, S., Forlenzar, T. J., Penziner, A., Kanganis, D., Knowles, D., Traganos, F., and Silber, R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res., 48: 3537-3543, 1988.
21. Hwang, J., Shyy, S., Chen, A. Y., Juan, C-C., and Whang-Peng, J. Studies of topoisomerase-specific anti-tumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res., 49: 958-962, 1989.
22. Duguet, M., Lavenot, C., and Harper, F. DNA topoisomerase from rat liver: physiological variations. Nucleic Acids Res., 11: 1059-1073, 1983.
23. Liu, L. F., and Miller, K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78: 3487-3491, 1981.
24. Hwong, C. L., Chen, M. S., and Hwang, J. Phorbol ester transiently increases topoisomerase I mRNA levels in human skin fibroblasts. J. Biol. Chem., 264: 14923-14926, 1989.
25. Pantazis, P., Early, J. A., Kozielski, A. J., Mendoza, J. T., Hinz, H. R., and Giovanella, B. C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res., 53: 1577-1582, 1993.
26. Pantazis, P., Kozielski, A. J., Mendoza, J. T., Early, J. A., Hinz, H. R., and Giovanella, B. C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between of nontumorigenic and tumorigenic cells in vitro. Int. J. Cancer, 53: 863-871, 1993.
27. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res., 57: 6039-6044, 1991.
28. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new Camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
29. Chen, A. Y., and Liu, L. F. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance in human cancers. In: L. F. Liu (ed.), DNA Topoisomerases Norwell, MA: Kluwer Academic Publishers, pp. 245-256, 1994.
30. Boothman, D. A., Trask, D. K., and Pardee, A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res., 49: 605-612, 1989.
31. Maltern, M. R., Hofmann, G. A., McCabe, F. L., and Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res., 51: 5813-5816, 1991.
32. Kim, J. H., Kim, S. H., Kolozsvary, A., and Khil, M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys., 22: 515-518, 1992.
33. Boothman, D. A., Wang, M., Schea, R. A., Burrows, H. L., Strickfaden, S., and Owens, J. K. Posttreatment exposure to Camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24: 939-948, 1992.
34. Roffler, S. R., Chan, J., and Yeh, M-Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res., 54: 1276-1285, 1994.
35. Boothman, D. A., Fukunaga, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618-4626, 1994.
36. Falk, S. J., and Smith, P. J. DNA damaging and cell cycle effects of the topoisomerase I poison Camptothecin in irradiated human cells. Int. J. Radiat. Biol., 61: 749-757, 1992.
37. Hennequin, C., Giocanti, N., Balosso, J., and Favaudon, V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res., 54: 1720-1728, 1994.
38. Tanizawa, A., and Pommier, Y. Topoisomerase I alteration in a camptothecinresistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res., 52: 1848-1854, 1992.
39. Tanizawa, A., Bertrand, R., Kohlhagen, G., Tabuchi, A., Jenkins, J., and Pommier, Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem., 268: 25463-25468, 1993.
40. Albright, N. Computer programs for the analysis of cellular survival data. Radiat. Res., 112: 331-340, 1987.
41. Cook, J. A., Glass, J., Lebovics, R., Bobo, H., Pass, H., DeLaney, T. F., Oldfield, E. H., Mitchell, J. B., Glatstein, E., and Goffman, T. E. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res., 52: 719-725, 1992.
42. O'Connor, P. M., Kerrigan, D., Bertrand, R., Kohn, K. W., and Pommier, Y. 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Commun., 3: 233-240, 1990.
43. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
44. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Kirshenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res., 49: 4385-4389, 1989.
45. 34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
46. Burke, T. G., Malak, H., Doroshow, J., Chen, A., and Liu, L. Model membrane interactions of camptothecin probed using fluorescence technique. Proc. Am. Assoc. Cancer Res., 33: 2602, 1992.
47. Burke, T. G., Mishra, A. K., Wani, M. C., and Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.